EUVIMEDEUVIMED entdecken
Crossref

Association of claudin 18.2 expression with outcomes of ramucirumab plus paclitaxel as second-line therapy in advanced gastric cancer

Mi-Ran Han, Ji Eun Shin, Sung Hee Lim, Jeeyun Lee, Seung Tae Kim

World Journal of Gastrointestinal Oncology · 13.05.2026

DOI: 10.4251/wjgo.121158 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Gastrointestinal Oncology, online erschienen am 13.05.2026. Verfasst von Mi-Ran Han und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Ramucirumab plus paclitaxel remains the standard second-line treatment for advanced gastric cancer (AGC), despite evolving frontline therapies. However, the prognostic and predictive significance of claudin 18.2 (CLDN18.2) expression in this setting remains unclear. AIM To evaluate the prognostic and predictive significance of CLDN18.2 expression in patients with AGC treated with ramucirumab plus paclitaxel. METHODS This retrospective study included patients with AGC who underwent treatment with ramucirumab plus paclitaxel as second-line therapy between January 2023 and October 2025, and had available CLDN18.2 data. CLDN18.2 positivity was defined as membranous staining in ≥ 75% of tumor cells. Survival outcomes were analyzed using Kaplan-Meier estimates and Cox models, with restricted mean survival time applied when proportional hazards assumptions were not met. RESULTS Among 103 patients, 42 (40.8%) and 61 (59.2%) were CLDN18.2-positive and CLDN18.2-negative, respectively. Baseline clinical and molecular characteristics did not differ significantly between the two groups. CLDN18.2 expression status was not associated with overall survival (hazard ratio = 1.12; 95%CI: 0.67-1.86; P = 0.666). Restricted mean survival time analysis also showed comparable survival between the two groups (12.7 months vs 13.3 months; P = 0.753). Progression-free survival did not differ significantly according to CLDN18.2 expression status (hazard ratio = 1.14; 95%CI: 0.70-1.85; P = 0.595), and objective response rate did not differ significantly between the two groups (30.6% vs 35.1%; P = 0.822). CONCLUSION CLDN18.2 expression is not associated with outcomes of ramucirumab plus paclitaxel second-line therapy and may have limited utility for treatment selection in AGC.

Zitieren

APA

Han, M., Shin, J. E., Lim, S. H., Lee, J., & Kim, S. T. (2026). Association of claudin 18.2 expression with outcomes of ramucirumab plus paclitaxel as second-line therapy in advanced gastric cancer. World Journal of Gastrointestinal Oncology. https://doi.org/10.4251/wjgo.121158

Vancouver

Han M, Shin JE, Lim SH, Lee J, Kim ST. Association of claudin 18.2 expression with outcomes of ramucirumab plus paclitaxel as second-line therapy in advanced gastric cancer. World Journal of Gastrointestinal Oncology. 2026. doi:10.4251/wjgo.121158

BibTeX
@article{Han2026,
  author = {Han, Mi-Ran and Shin, Ji Eun and Lim, Sung Hee and Lee, Jeeyun and Kim, Seung Tae},
  title = {Association of claudin 18.2 expression with outcomes of ramucirumab plus paclitaxel as second-line therapy in advanced gastric cancer},
  journal = {World Journal of Gastrointestinal Oncology},
  year = {2026},
  doi = {10.4251/wjgo.121158}
}
Kostenlos starten →